India · Delayed Price · Currency is INR Windlas Biotech Statistics
Total Valuation
Windlas Biotech has a market cap or net worth of INR 21.05 billion. The enterprise value is 18.96 billion.
| Market Cap | 21.05B |
| Enterprise Value | 18.96B |
Important Dates
The last earnings date was Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | Jul 16, 2026 |
Share Statistics
Windlas Biotech has 20.64 million shares outstanding. The number of shares has increased by 0.55% in one year.
| Current Share Class | 20.64M |
| Shares Outstanding | 20.64M |
| Shares Change (YoY) | +0.55% |
| Shares Change (QoQ) | -0.61% |
| Owned by Insiders (%) | 63.43% |
| Owned by Institutions (%) | 9.02% |
| Float | 7.23M |
Valuation Ratios
The trailing PE ratio is 32.62.
| PE Ratio | 32.62 |
| Forward PE | n/a |
| PS Ratio | 2.10 |
| PB Ratio | 3.66 |
| P/TBV Ratio | 3.70 |
| P/FCF Ratio | 46.92 |
| P/OCF Ratio | 20.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.52, with an EV/FCF ratio of 42.22.
| EV / Earnings | 28.11 |
| EV / Sales | 1.89 |
| EV / EBITDA | 16.52 |
| EV / EBIT | 22.27 |
| EV / FCF | 42.22 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.66 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.47 |
| Debt / FCF | 1.20 |
| Interest Coverage | 12.50 |
Financial Efficiency
Return on equity (ROE) is 12.09% and return on invested capital (ROIC) is 18.64%.
| Return on Equity (ROE) | 12.09% |
| Return on Assets (ROA) | 5.75% |
| Return on Invested Capital (ROIC) | 18.64% |
| Return on Capital Employed (ROCE) | 14.59% |
| Weighted Average Cost of Capital (WACC) | 6.22% |
| Revenue Per Employee | 7.17M |
| Profits Per Employee | 481,567 |
| Employee Count | 1,385 |
| Asset Turnover | 1.09 |
| Inventory Turnover | 6.64 |
Taxes
In the past 12 months, Windlas Biotech has paid 196.71 million in taxes.
| Income Tax | 196.71M |
| Effective Tax Rate | 22.78% |
Stock Price Statistics
The stock price has increased by +21.21% in the last 52 weeks. The beta is 0.34, so Windlas Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +21.21% |
| 50-Day Moving Average | 1,011.79 |
| 200-Day Moving Average | 875.70 |
| Relative Strength Index (RSI) | 58.29 |
| Average Volume (20 Days) | 157,088 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Windlas Biotech had revenue of INR 9.93 billion and earned 666.97 million in profits. Earnings per share was 31.27.
| Revenue | 9.93B |
| Gross Profit | 3.83B |
| Operating Income | 841.84M |
| Pretax Income | 863.68M |
| Net Income | 666.97M |
| EBITDA | 1.11B |
| EBIT | 841.84M |
| Earnings Per Share (EPS) | 31.27 |
Balance Sheet
The company has 2.62 billion in cash and 534.29 million in debt, with a net cash position of 2.09 billion or 101.19 per share.
| Cash & Cash Equivalents | 2.62B |
| Total Debt | 534.29M |
| Net Cash | 2.09B |
| Net Cash Per Share | 101.19 |
| Equity (Book Value) | 5.69B |
| Book Value Per Share | 275.85 |
| Working Capital | 2.88B |
Cash Flow
In the last 12 months, operating cash flow was 1.02 billion and capital expenditures -580.87 million, giving a free cash flow of 444.02 million.
| Operating Cash Flow | 1.02B |
| Capital Expenditures | -580.87M |
| Depreciation & Amortization | 265.23M |
| Net Borrowing | 160.76M |
| Free Cash Flow | 444.02M |
| FCF Per Share | 21.52 |
Margins
Gross margin is 38.58%, with operating and profit margins of 8.48% and 6.72%.
| Gross Margin | 38.58% |
| Operating Margin | 8.48% |
| Pretax Margin | 8.70% |
| Profit Margin | 6.72% |
| EBITDA Margin | 11.15% |
| EBIT Margin | 8.48% |
| FCF Margin | 4.47% |
Dividends & Yields
This stock pays an annual dividend of 6.30, which amounts to a dividend yield of 0.62%.
| Dividend Per Share | 6.30 |
| Dividend Yield | 0.62% |
| Dividend Growth (YoY) | 8.62% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 19.49% |
| FCF Payout Ratio | 34.88% |
| Buyback Yield | -0.55% |
| Shareholder Yield | 0.08% |
| Earnings Yield | 3.07% |
| FCF Yield | 2.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |